| Symbol | ASRT |
|---|---|
| Name | ASSERTIO HOLDINGS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100 SOUTH SANDERS RD.,SUITE 300, LAKE FOREST, Illinois, 60045, United States |
| Telephone | +1 224 - 419-7106 |
| Fax | — |
| — | |
| Website | https://www.assertiotx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. Additional info from NASDAQ: |
(99% Neutral) ASSERTIO HOLDINGS, INC. (ASRT) Announces Business Combination
Read moreAssertio Holdings, Inc. - Assertio Provides Update on Garda Therapeutics Tender Process
Read moreNew Form SC14D9C - Assertio Holdings, Inc. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001104659-26-046150 <b>Size:</b> 22 KB
Read more(99% Neutral) ASSERTIO HOLDINGS, INC. (ASRT) Reports Q2 2026 Financial Results
Read moreNew Form SC14D9C - Assertio Holdings, Inc. <b>Filed:</b> 2026-04-14 <b>AccNo:</b> 0001104659-26-043277 <b>Size:</b> 23 KB
Read moreAssertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT
Read moreASRT Stock Alert: Halper Sadeh LLC is Investigating Whether Assertio Holdings, Inc. is Obtaining a Fair Price for its Shareholders
Read moreNew Form SC14D9C - Assertio Holdings, Inc. <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001104659-26-041576 <b>Size:</b> 25 KB
Read moreNew Form SC TO-C - Assertio Holdings, Inc. <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001104659-26-041570 <b>Size:</b> 1 MB
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Diphenhydramine | DRUG | Phase PHASE2 | Headache, Migraine | TERMINATED | NCT06083571 |
| Prochlorperazine | DRUG | Phase PHASE2 | Headache, Migraine | TERMINATED | NCT06083571 |
| Ketorolac | DRUG | Phase PHASE2 | Headache, Migraine | TERMINATED | NCT06083571 |